Mallinckrodt announced that it has reached agreement with the U.S. Federal Trade Commission (FTC) to resolve, without admission of wrongdoing, the previously disclosed FTC investigation into the acquisition by Questcor Pharmaceuticals, Inc., of Synacthen®